CMPS NASDAQ
COMPASS Pathways plc
1W: -0.8%
1M: -10.7%
3M: +8.3%
YTD: +80.3%
1Y: +88.1%
3Y: +104.0%
5Y: -65.0%
$11.81
+0.76 (+6.88%)
After Hours: $11.78 (-0.03, -0.25%)
Weekly Expected Move ±7.8%
$9
$10
$11
$12
$13
Credit Risk of going bust: higher than 56% of companies Debt: 3.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.06 (down 99.5%), COMPASS Pathways plc would be worth roughly what it owes.
Total debt $54.6M against a stock market value of $1.53B.
Distance to default 4.55 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $25.4M (short-term plus half of long-term), stock volatility 85.1%; Altman Z'' -9.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $54.6M against a stock market value of $1.53B.
Distance to default 4.55 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $25.4M (short-term plus half of long-term), stock volatility 85.1%; Altman Z'' -9.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.6B
52W Range4.88-15.87
Volume2,268,758
Avg Volume3,219,238
Beta2.56
Dividend—
Analyst Ratings
Company Info
CEOKabir Kumar Nath
Employees156
SectorHealthcare
IndustryBiotechnology
IPO Date2020-09-18
Websitecompasspathways.com
33 Broadwick Street
London, CH W1F 0DQ
GB
London, CH W1F 0DQ
GB
44 64 6905 3974
About COMPASS Pathways plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Latest News
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokerages
How Is COMPASS Pathways (CMPS) Shaping TRD Care Beyond Clinical Trial Results? - simplywall.st
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nath Kabir | F-InKind | 5,962 | $11.25 | 2026-08-03 |
| Riley Wayne Joseph | A-Award | 21,110 | $11.85 | 2026-05-27 |
| McQuade Robert | A-Award | 21,110 | $11.85 | 2026-05-27 |
| Norton David Y | A-Award | 21,110 | $11.85 | 2026-05-27 |
| Tregoning Kathleen | A-Award | 41,119 | $11.85 | 2026-05-27 |